Las carteras farmacéutica y de dispositivos médicos de Johnson & Johnson están bien posicionadas para beneficiarse de poblaciones envejecidas que impulsan una mayor demanda de tratamientos de oncología, inmunología y cirugía.
Johnson & Johnson es una acción blue chip quintaesencial con más de 130 años de historia operativa, una calificación crediticia AAA que poseen muy pocas corporaciones, y un negocio de salud diversificado que proporciona estabilidad a través de prácticamente cualquier ciclo económico.
Johnson & Johnson es un gigante del sector salud con más de 60 años consecutivos de aumentos de dividendos, respaldado por franquicias farmacéuticas y de dispositivos médicos líderes en mercados globales.
Johnson & Johnson es un Dividend King con más de 60 años consecutivos de aumentos de dividendos anuales, respaldado por los flujos de efectivo estables y resistentes a las recesiones de sus negocios farmacéuticos y de dispositivos médicos. Su larga trayectoria de crecimiento de dividendos confiable la convierte en una acción de dividendos premier para inversores que buscan ingresos confiables del sector salud.
Data updated Feb 15 · Source: Twelve Data
Johnson & Johnson remains one of the most dependable names in healthcare investing. Following its Kenvue consumer health spinoff, JNJ is now a focused pharmaceutical and MedTech company, better positioned to capitalize on aging demographics through oncology, immunology, and surgical innovations.
The stock has surged nearly 57% over the past year, now trading near its 52-week high of $246.35 and well above its 50-day moving average. This rally has stretched the P/E ratio to 32.37"elevated relative to historical norms"raising valuation concerns for new entrants. EPS of $7.52 reflects solid but not exceptional earnings power.
As a Dividend Aristocrat with 60+ consecutive years of increases, JNJ's income reliability is unmatched, though the current yield has compressed due to price appreciation. The pharmaceutical pipeline, including Darzalex and Tremfya, provides meaningful growth catalysts, while MedTech benefits from procedure volume recovery.
Key risks include ongoing talc litigation liabilities, patent cliffs on major drugs, and the premium valuation. The bull case centers on pipeline execution, demographic tailwinds, and defensive positioning during economic uncertainty. A strong core holding, though dollar-cost averaging may be prudent at current levels.
Johnson & Johnson remains a definitive blue-chip holding, recently demonstrating robust momentum as it trades near its 52-week high of $240.94. Following its strategic restructuring to focus on high-growth pharmaceutical and MedTech segments, the stock has surged well above its 50-day moving average. However, the current valuation warrants caution; at a P/E ratio of 31.70, JNJ is trading at a significant premium to its historical range, suggesting that optimistic growth expectations are already priced in. While the company's legendary status as a Dividend King continues to attract income investors seeking stability, the stretched multiple may limit near-term upside. JNJ represents a high-quality defensive play with a fortress balance sheet, but value-conscious investors might prefer to wait for a pullback before adding to positions.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Cada trader tiene una estrategia que se ve genial en su cabeza. El backtesting es cómo descubres si realmente funciona. Aquí hay cómo probar estrategias correctamente, qué métricas importan y por qué la mayoría de los resultados de backtest son demasiado buenos para ser verdad.
Powered by Rexiew